Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

35.35 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Earnings Scheduled For May 1, 2025
Via Benzinga
An Overview of Agios Pharmaceuticals's Earnings
Via Benzinga
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results. 
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
Via Benzinga
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
The company is currently seeking approval for its thalassemia treatment in four regions. 
Via Investor's Business Daily
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
4 Analysts Have This To Say About Agios Pharmaceuticals
Via Benzinga
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary... 
Via Benzinga
Expert Ratings For Agios Pharmaceuticals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?
Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of... 
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nvidia Again Boosts Nasdaq To Record Highs
The Nasdaq Composite Index is extending Friday's record highs, with help from Nvidia, which is up 5% at last glance and marking its own all-time highs. 
Via Talk Markets
Topics Stocks
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Attention Biotech Investors - Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.